Clinical trial
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell…
NCT00095186 · Agennix, Industry · Completed
Key facts
| NCT number | NCT00095186 |
|---|---|
| Title | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma |
| Official title | A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant Human Lactoferrin (rhLF) Monotherapy in Patients With Advanced Renal Cell Carcinoma (RCC), Who Have Failed at Least One Regimen of Systemic Therapy for RCC |
| Lead sponsor | Agennix, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Recombinant Human Lactoferrin |
| Enrollment | 40 |
| Start date | Sep 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Nov 2, 2004 |
| Last update posted | Apr 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: